558 related articles for article (PubMed ID: 22888605)
1. Human adenovirus-vectored foot-and-mouth disease vaccines: establishment of a vaccine product profile through in vitro testing.
Brake DA; McIlhaney M; Miller T; Christianson K; Keene A; Lohnas G; Purcell C; Neilan J; Schutta C; Barrera J; Burrage T; Brough DE; Butman BT
Dev Biol (Basel); 2012; 134():123-33. PubMed ID: 22888605
[TBL] [Abstract][Full Text] [Related]
2. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response.
Moraes MP; Segundo FD; Dias CC; Pena L; Grubman MJ
Vaccine; 2011 Nov; 29(51):9431-40. PubMed ID: 22027486
[TBL] [Abstract][Full Text] [Related]
3. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals.
Grubman MJ
Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996
[TBL] [Abstract][Full Text] [Related]
4. Duration of protection and humoral immunity induced by an adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in Holstein steers.
Sitt T; Kenney M; Barrera J; Pandya M; Eckstrom K; Warner M; Pacheco JM; LaRocco M; Palarea-Albaladejo J; Brake D; Rieder E; Arzt J; Barlow JW; Golde WT
Vaccine; 2019 Sep; 37(42):6221-6231. PubMed ID: 31493951
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a Fiber-Modified Adenovirus Vector Vaccine against Foot-and-Mouth Disease in Cattle.
Medina GN; Montiel N; Diaz-San Segundo F; Sturza D; Ramirez-Medina E; Grubman MJ; de los Santos T
Clin Vaccine Immunol; 2015 Nov; 23(2):125-36. PubMed ID: 26607309
[TBL] [Abstract][Full Text] [Related]
6. Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle.
Barrera J; Brake DA; Kamicker BJ; Purcell C; Kaptur R; Schieber T; Lechtenberg K; Miller TD; Ettyreddy D; Brough DE; Butman BT; Colby M; Neilan JG
Transbound Emerg Dis; 2018 Apr; 65(2):447-455. PubMed ID: 29076657
[TBL] [Abstract][Full Text] [Related]
7. Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.
Barrera J; Schutta C; Pisano M; Grubman MJ; Brake DA; Miller T; Kamicker BJ; Olutunmbi F; Ettyreddy D; Brough DE; Butman BT; Neilan JG
Vaccine; 2018 Feb; 36(8):1078-1084. PubMed ID: 29358056
[TBL] [Abstract][Full Text] [Related]
8. Chimeric foot-and-mouth disease viruses: evaluation of their efficacy as potential marker vaccines in cattle.
Fowler VL; Paton DJ; Rieder E; Barnett PV
Vaccine; 2008 Apr; 26(16):1982-9. PubMed ID: 18342409
[TBL] [Abstract][Full Text] [Related]
9. Delivery of a foot-and-mouth disease virus empty capsid subunit antigen with nonstructural protein 2B improves protection of swine.
Pena L; Moraes MP; Koster M; Burrage T; Pacheco JM; Segundo FD; Grubman MJ
Vaccine; 2008 Oct; 26(45):5689-99. PubMed ID: 18762225
[TBL] [Abstract][Full Text] [Related]
10. Engineering better vaccines for foot-and-mouth disease.
Mason PW; Chinsangaram J; Moraes MP; Mayr GA; Grubman MJ
Dev Biol (Basel); 2003; 114():79-88. PubMed ID: 14677679
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human adenovirus-5 expressing capsid proteins of Indian vaccine strains of foot-and-mouth disease virus elicits effective antibody response in cattle.
Sreenivasa BP; Mohapatra JK; Pauszek SJ; Koster M; Dhanya VC; Tamil Selvan RP; Hosamani M; Saravanan P; Basagoudanavar SH; de Los Santos T; Venkataramanan R; Rodriguez LL; Grubman MJ
Vet Microbiol; 2017 May; 203():196-201. PubMed ID: 28619144
[TBL] [Abstract][Full Text] [Related]
12. Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine.
Barrera J; Brake DA; Schutta C; Ettyreddy D; Kamicker BJ; Rasmussen MV; Bravo de Rueda C; Zurita M; Pisano M; Hurtle W; Brough DE; Butman BT; Harper BG; Neilan JG
Vaccine; 2018 Nov; 36(48):7345-7352. PubMed ID: 30327212
[TBL] [Abstract][Full Text] [Related]
13. Immune responses of recombinant adenovirus co-expressing VP1 of foot-and-mouth disease virus and porcine interferon alpha in mice and guinea pigs.
Du Y; Dai J; Li Y; Li C; Qi J; Duan S; Jiang P
Vet Immunol Immunopathol; 2008 Aug; 124(3-4):274-83. PubMed ID: 18511133
[TBL] [Abstract][Full Text] [Related]
14. Avidity and subtyping of specific antibodies applied to the indirect assessment of heterologous protection against Foot-and-Mouth Disease Virus in cattle.
Lavoria MÁ; Di-Giacomo S; Bucafusco D; Franco-Mahecha OL; Pérez-Filgueira DM; Capozzo AV
Vaccine; 2012 Nov; 30(48):6845-50. PubMed ID: 23000129
[TBL] [Abstract][Full Text] [Related]
15. Cedivac-FMD can be used according to a marker vaccine principle.
Chénard G; Selman P; Dekker A
Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine in cattle using a direct contact transmission model.
Neilan JG; Schutta C; Barrera J; Pisano M; Zsak L; Hartwig E; Rasmussen MV; Kamicker BJ; Ettyreddy D; Brough DE; Butman BT; Brake DA
BMC Vet Res; 2018 Aug; 14(1):254. PubMed ID: 30157853
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of modified Vaccinia Ankara-based vaccines against foot-and-mouth disease serotype A24 in cattle.
Steigerwald R; Brake DA; Barrera J; Schutta CJ; Kalla M; Wennier ST; Volkmann A; Hurtle W; Clark BA; Zurita M; Pisano M; Kamicker BJ; Puckette MC; Rasmussen MV; Neilan JG
Vaccine; 2020 Jan; 38(4):769-778. PubMed ID: 31718901
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immune responses to different foot-and-mouth disease genetically engineered vaccines in guinea pigs.
Yao Q; Qian P; Huang Q; Cao Y; Chen H
J Virol Methods; 2008 Jan; 147(1):143-50. PubMed ID: 17963851
[TBL] [Abstract][Full Text] [Related]
19. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine.
Qian P; Li XM; Jin ML; Peng GQ; Chen HC
Vaccine; 2004 Jun; 22(17-18):2129-36. PubMed ID: 15149769
[TBL] [Abstract][Full Text] [Related]
20. Updating of the correlation between lpELISA titers and protection from virus challenge for the assessment of the potency of polyvalent aphtovirus vaccines in Argentina.
Maradei E; La Torre J; Robiolo B; Esteves J; Seki C; Pedemonte A; Iglesias M; D'Aloia R; Mattion N
Vaccine; 2008 Dec; 26(51):6577-86. PubMed ID: 18835312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
